. 2016 May 28;22(20):4812–4823. doi: 10.3748/wjg.v22.i20.4812

Table 3.

Ongoing trials

Name	Indication	Line	Agent	ClinicalTrials.gov Identifier
Phase	Indication	Line	Agent	ClinicalTrials.gov Identifier
HER2
HELOISE	HER2(+) Met GC and GEJ	1^st	Trastuzumab	NCT01450696
Phase III	HER2(+) Met GC and GEJ	1^st	Trastuzumab	NCT01450696
JACOB	HER2(+) Met GC and GEJ	1^st	Pertuzumab	NCT01774786
Phase III	HER2(+) Met GC and GEJ	1^st	Pertuzumab	NCT01774786
VEGFR
RAINFALL	HER2(-) Met GC and GEJ	1^st	Ramucirumab	NCT02314117
Phase III	HER2(-) Met GC and GEJ	1^st	Ramucirumab	NCT02314117
PARP
Olaparib	Adv GC and GEJ	2^nd	Olaparib	NCT01924533
Phase III	Adv GC and GEJ	2^nd	Olaparib	NCT01924533
Immune checkpoints
KEYNOTE-059	Adv GC and GEJ		Pembrolizumab	NCT02335411
Phase II	Adv GC and GEJ		Pembrolizumab	NCT02335411
KEYNOTE-061	Adv GC and GEJ	2^nd	Pembrolizumab	NCT02370498
Phase III	Adv GC and GEJ	2^nd	Pembrolizumab	NCT02370498
KEYNOTE-062	Adv GC and GEJ	1^st	Pembrolizumab	NCT02494583
Phase III	Adv GC and GEJ	1^st	Pembrolizumab	NCT02494583
MEDI4736	Advanced solid tumors		MEDI4736	NCT01693562
Phase I/II	Advanced solid tumors		MEDI4736	NCT01693562
JAVELIN Gastric 100	Adv/Met GC and GEJ	1^st	Avelumab	NCT02625610
Phase III	Adv/Met GC and GEJ	1^st	Avelumab	NCT02625610
JAVELIN Gastric 300	Met/recurrent GC and GEJ	3^rd	Avelumab	NCT02625623
Phase III	Met/recurrent GC and GEJ	3^rd	Avelumab	NCT02625623
Phase I/II	Met/recurrent GC and GEJ		MEDI4736 + Tremelimumab vs MEDI4736 vs Tremelimumab	NCT02340975
Phase I/II	Advanced solid tumors		Nivolumab +/- Ipilimumab	NCT01928394

Adv: Advanced; Met: Metastatic; GC: Gastric cancer; GEJ: Gastroesophageal junction; HER2: Human epidermal growth factor receptor 2; VEGFR: Vascular endothelial growth factor receptor; PARP: Poly ADP-ribose polymerase.